Suppr超能文献

解决间充质干细胞/基质细胞免疫调节谱异质性以改善基于细胞的治疗策略。

Strategies to address mesenchymal stem/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies.

机构信息

Cell Sheet Tissue Engineering Center (CSTEC), University of Utah, Salt Lake City, Utah, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.

Cell Sheet Tissue Engineering Center (CSTEC), University of Utah, Salt Lake City, Utah, USA; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah, USA.

出版信息

Acta Biomater. 2021 Oct 1;133:114-125. doi: 10.1016/j.actbio.2021.03.069. Epub 2021 Apr 20.

Abstract

Mesenchymal stromal cells (MSCs) have gained immense attention over the past two decades due to their multipotent differentiation potential and pro-regenerative and immunomodulatory cytokine secretory profiles. Their ability to modulate the host immune system and promote tolerance has prompted several allogeneic and autologous hMSC-based clinical trials for the treatment of graft-versus-host disease and several other immune-induced disorders. However, clinical success beyond safety is still controversial and highly variable, with inconclusive therapeutic benefits and little mechanistic explanation. This clinical variability has been broadly attributed to inconsistent MSC sourcing, phenotypic characterization, variable potency, and non-standard isolation protocols, leading to functional heterogeneity among administered MSCs. Homogeneous MSC populations are proposed to yield more predictable, reliable biological responses and clinically meaningful properties relevant to cell-based therapies. Limited comparisons of heterogeneous MSCs with homogenous MSCs are reported. This review addresses this gap in the literature with a critical analysis of strategies aimed at decreasing MSC heterogeneity concerning their reported immunomodulatory profiles. STATEMENT OF SIGNIFICANCE: This review collates, summarizes, and critically analyzes published strategies that seek to improve homogeneity in immunomodulatory functioning MSC populations intended as cell therapies to treat immune-based disorders, such as graft-vs-host-disease. No such review for MSC therapies, immunomodulatory profiles and cell heterogeneity analysis is published. Since MSCs represent the most clinically studied experimental cell therapy platform globally for which there remains no US domestic marketing approval, insights into MSC challenges in therapeutic product development are imperative to providing solutions for immunomodulatory variabilities.

摘要

间充质基质细胞 (MSCs) 在过去二十年中受到了极大的关注,因为它们具有多能分化潜力和促再生及免疫调节细胞因子分泌谱。它们调节宿主免疫系统和促进耐受性的能力促使进行了几项同种异体和自体 hMSC 为基础的临床试验,以治疗移植物抗宿主病和其他几种免疫诱导疾病。然而,超出安全性的临床成功仍然存在争议,且高度可变,治疗益处不确定,机制解释很少。这种临床变异性广泛归因于 MSC 来源不一致、表型特征、变异性能力和非标准分离方案,导致给予的 MSCs 之间存在功能异质性。同质 MSC 群体被认为可产生更可预测、可靠的生物学反应和与细胞治疗相关的有临床意义的特性。据报道,对异质 MSCs 与同质 MSCs 进行了有限的比较。本综述通过对旨在降低 MSC 异质性的策略进行批判性分析,填补了这一文献空白,这些策略涉及到它们报道的免疫调节谱。 意义声明:本综述汇集、总结和批判性分析了已发表的策略,这些策略旨在提高作为治疗免疫相关疾病(如移植物抗宿主病)的细胞疗法的同质 MSC 群体的免疫调节功能的均一性。目前还没有关于 MSC 疗法、免疫调节谱和细胞异质性分析的此类综述。由于 MSCs 是全球最具临床研究经验的实验性细胞治疗平台,而美国国内尚未批准任何此类治疗方法,因此了解 MSC 在治疗产品开发中的挑战对于解决免疫变异性问题至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验